

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}			
Set of samples 1																	
(81) Digoxin					125			0				125	111	89%			
Samples and groups		[nmol/L]															
Sample A1		1,02	0,21	21	125			0	CRV	1,018	,0100	36%	0,651	1,39	125	119	95%
(1) Abbott		0,780	0,12	15	35	0									35		
(12) Beckman Coulter		1,12	0,09	8,6	12	0									12		
(29) Siemens (DPC)		1,06	0,07	6,9	7	0									7		
(58) Beckman Coulter (Olympus)		1,09	0,10	9,1	11	0									11		
(60) Roche		1,11	0,16	15	34	0									34		
(179) Siemens (Bayer)		1,19	0,09	8,3	18	0									18		
Other					8	0									8		
										1x 0, 3x 149, 2x 166, 2x 177							
Sample B1		0,842	0,18	22	125			0	CRV	0,846	,0085	36%	0,541	1,16	125	113	90%
(1) Abbott		0,629	0,11	18	35	0									35		
(12) Beckman Coulter		0,911	0,07	7,9	12	0									12		
(29) Siemens (DPC)		0,845	0,13	16	7	0									7		
(58) Beckman Coulter (Olympus)		0,947	0,14	15	11	0									11		
(60) Roche		0,916	0,13	14	34	0									34		
(179) Siemens (Bayer)		0,958	0,09	9,5	18	0									18		
Other					8	0									8		
										1x 0, 3x 149, 2x 166, 2x 177							
(82) Theophylline					88			0				88	87	99%			
Samples and groups		[µmol/L]															
Sample A1		87,2	5,9	6,7	88			0	CRV	88,1	0,88	24%	66,9	110	88	88	100%
(1) Abbott		85,2	5,8	6,8	24	0									24		
(12) Beckman Coulter		80,9	6,4	7,9	6	0									6		
(29) Siemens (DPC)		84,2	7,2	8,6	5	0									5		
(58) Beckman Coulter (Olympus)		85,7	3,9	4,5	9	0									9		
(60) Roche		88,4	4,1	4,6	28	0									28		
(179) Siemens (Bayer)		95,6	7,6	8,0	11	0									11		
Other					5	0									5		
										1x 0, 1x 149, 2x 166, 1x 177							
Sample B1		81,4	5,2	6,4	88			0	CRV	80,99	0,81	24%	61,5	101	88	87	99%
(1) Abbott		79,2	4,6	5,8	24	0									24		
(12) Beckman Coulter		76,0	6,7	8,8	6	0									6		
(29) Siemens (DPC)		81,6	0,77	0,94	5	0									5		
(58) Beckman Coulter (Olympus)		80,1	4,8	6,0	9	1									9		
(60) Roche		82,7	2,9	3,5	28	0									28		
(179) Siemens (Bayer)		90,2	7,9	8,8	11	0									11		
Other					5	0									5		
										1x 0, 1x 149, 2x 166, 1x 177							

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(83) Primidone						8							8	7	88%								0
Samples and groups	[µmol/L]																						
Sample A1		19,2	4,1	22	8	CVP	19,2	3,2	24%	14,5	23,9	8	8	100%								0	
(999) another manufacturer		19,8	3,2	16	5	0						5											
Other					3	0						3											
						1x 60, 2x 118																	
Sample B1		42,6	6,0	14	8	CVP	42,6	4,6	24%	32,3	52,9	8	7	88%								0	
(999) another manufacturer		42,6	6,0	14	5	0						5											
Other					3	0						3											
						1x 60, 2x 118																	
(84) Phenobarbital						27							27	26	96%								0
Samples and groups	[µmol/L]																						
Sample A1		70,3	4,4	6,3	27	CVP	70,3	2,1	20%	56,2	84,4	27	26	96%								0	
(1) Abbott		71,0	3,5	4,9	10	0						10											
(60) Roche		67,7	4,5	6,7	9	0						9											
Other					8	0						8											
						1x 0, 2x 58, 1x 118, 1x 179, 3x 999																	
Sample B1		97,7	4,2	4,3	27	CVP	97,7	2,0	20%	78,1	118	27	27	100%								0	
(1) Abbott		98,8	3,7	3,7	10	0						10											
(60) Roche		94,6	2,7	2,9	9	0						9											
Other					8	0						8											
						1x 0, 2x 58, 1x 118, 1x 179, 3x 999																	
(85) Phenytoin						46							46	46	100%								0
Samples and groups	[µmol/L]																						
Sample A1		83,3	4,1	4,9	46	CVP	83,3	1,5	20%	66,6	100	46	46	100%								0	
(1) Abbott		82,8	3,3	4,0	15	0						15											
(60) Roche		84,7	3,9	4,6	15	0						15											
Other					16	0						16											
						2x 12, 3x 29, 3x 58, 1x 118, 1x 149, 3x 179, 3x 999																	
Sample B1		28,0	1,9	6,8	46	CVP	28,0	0,69	20%	22,4	33,6	46	46	100%								0	
(1) Abbott		28,3	1,4	5,0	15	0						15											
(60) Roche		28,5	1,5	5,3	15	0						15											
Other					16	0						16											
						2x 12, 3x 29, 3x 58, 1x 118, 1x 149, 3x 179, 3x 999																	
(86) Carbamazepin						64							64	63	98%								0
Samples and groups	[µmol/L]																						
Sample A1		39,5	2,7	6,8	64	CVP	39,5	0,82	20%	31,6	47,4	64	63	98%								0	
(1) Abbott		38,2	1,2	3,1	19	0						19											
(29) Siemens (DPC)		34,7	2,7	7,9	6	0						6											
(60) Roche		39,8	1,5	3,7	20	0						20											
(179) Siemens (Bayer)		40,5	4,3	11	6	0						6											
Other					13	0						13											
						1x 0, 1x 9, 2x 12, 4x 58, 1x 118, 1x 149, 3x 999																	
Sample B1		38,6	2,6	6,8	64	CVP	38,6	0,80	20%	30,8	46,4	64	64	100%								0	
(1) Abbott		37,4	1,9	5,0	19	0						19											
(29) Siemens (DPC)		33,6	1,6	4,9	6	0						6											
(60) Roche		39,1	1,4	3,5	20	0						20											
(179) Siemens (Bayer)		40,4	2,3	5,7	6	0						6											

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

Test	[unit]	Comparability						Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(86) Carbamazepin	[µmol/L]				64							64	63	98%									0	
Samples and groups																								
Sample B1		38,6	2,6	6,8	64		CVP	38,6	0,80	20%	30,8	46,4	64	64	100%									0
Other					13	0							13											
								1x 0, 1x 9, 2x 12, 4x 58, 1x 118, 1x 149, 3x 999																
(87) Ethosuximide	[µmol/L]				8								8	8	100%									0
Samples and groups																								
Sample A1		361	20	5,4	8		CVP	361	15	24%	274	448	8	8	100%									0
(999) another manufacturer		353	7,4	2,1	5	0							5											
Other					3	0							3											
								2x 118, 1x 179																
Sample B1		301	27	9,1	8		CVP	301	21	24%	228	374	8	8	100%									0
(999) another manufacturer		300	27	8,9	5	0							5											
Other					3	0							3											
								2x 118, 1x 179																
(88) Valproic acid	[µmol/L]				82								82	80	98%									0
Samples and groups																								
Sample A1		622	49	8,0	82		CVP	622	13	20%	497	747	82	81	99%									0
(1) Abbott		571	24	4,2	23	0							23											
(29) Siemens (DPC)		635	34	5,4	8	0							8											
(58) Beckman Coulter (Olympus)		691	55	7,9	7	0							7											
(60) Roche		635	29	4,6	28	0							28											
(179) Siemens (Bayer)		640	35	5,4	10	0							10											
Other					6	0							6											
								2x 0, 3x 12, 1x 149																
Sample B1		279	28	10	82		CVP	279	7,6	20%	223	335	82	80	98%									0
(1) Abbott		253	11	4,4	23	0							23											
(29) Siemens (DPC)		282	38	13	8	0							8											
(58) Beckman Coulter (Olympus)		309	13	4,3	7	0							7											
(60) Roche		286	17	5,9	28	0							28											
(179) Siemens (Bayer)		294	24	8,0	10	0							10											
Other					6	0							6											
								2x 0, 3x 12, 1x 149																
Set of samples 2																								
(89) Amicacin	[µmol/L]				30								30	27	90%									0
Samples and groups																								
Sample A2		32,0	2,2	7,0	30		CVP	32	1,00	20%	25,6	38,4	30	27	90%									0
(60) Roche		31,4	1,5	4,9	18	0							18											
Other					12	0							12											
								1x 0, 4x 1, 3x 12, 2x 58, 1x 149, 1x 166																
Sample B2		48,2	3,1	6,5	30		CVP	48,2	1,4	20%	38,5	57,9	30	28	93%									0
(60) Roche		47,6	2,5	5,3	18	0							18											
Other					12	0							12											
								1x 0, 4x 1, 3x 12, 2x 58, 1x 149, 1x 166																
(90) Gentamicin	[µmol/L]				55								55	51	93%									0
Samples and groups																								
Sample A2		7,66	0,88	11	55		CVP	7,66	0,29	31%	5,28	10,1	55	52	95%									0

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(90) Gentamicin					55							55	51	93%									0
Samples and groups	[µmol/L]																						
Sample A2		7,66	0,88	11	55	CVP	7,66	0,29	31%	5,28	10,1	55	52	95%									0
(1) Abbott		7,92	0,50	6,4	19							19											
(60) Roche		6,83	1,6	23	20							20											
(179) Siemens (Bayer)		7,88	0,60	7,6	8							8											
Other					8							8											
							2x 0, 3x 12, 3x 58																
Sample B2		15,6	2,9	19	55	CVP	15,6	0,97	31%	10,7	20,5	55	52	95%									0
(1) Abbott		16,6	1,2	7,1	19							19											
(60) Roche		13,3	2,6	19	20							20											
(179) Siemens (Bayer)		17,4	3,9	22	8							8											
Other					8							8											
							2x 0, 3x 12, 3x 58																
(92) Vancomycin					58							58	55	95%									0
Samples and groups	[µmol/L]																						
Sample A2		11,0	1,5	13	58	CVP	11	0,47	28%	7,92	14,1	58	56	97%									0
(1) Abbott		11,0	0,70	6,4	21							21											
(60) Roche		12,1	1,4	12	22							22											
(179) Siemens (Bayer)		8,94	0,57	6,4	9							9											
Other					6							6											
							2x 0, 2x 12, 1x 58, 1x 149																
Sample B2		28,8	4,0	14	58	CVP	28,8	1,3	28%	20,7	36,9	58	56	97%									0
(1) Abbott		28,4	1,9	6,6	21							21											
(60) Roche		31,5	4,3	14	22							22											
(179) Siemens (Bayer)		24,0	1,8	7,4	9							9											
Other					6							6											
							2x 0, 2x 12, 1x 58, 1x 149																
(93) Methotrexate					13							13	12	92%									0
Samples and groups	[µmol/L]																						
Sample A2		0,799	0,04	5,8	13	CVP	0,799	0,031	30%	0,559	1,04	13	12	92%									0
(1) Abbott		0,784	0,03	4,9	8							8											
Other					5							5											
							2x 60, 1x 166, 1x 179, 1x 999																
Sample B2		2,79	0,40	14	13	CVP	2,79	0,27	30%	1,95	3,63	13	12	92%									0
(1) Abbott		2,76	0,30	11	8							8											
Other					5							5											
							2x 60, 1x 166, 1x 179, 1x 999																

st_kn_np

End of report

Printed: 18.04.2018